Production and Application of Alpha Emitters

Session Organizers:
Alfred Morgenstern, European Commission Joint Research Centre, Institute for Transuranium Elements, Germany
Bryan Bednarz, University of Wisconsin, USA

The application of alpha emitting radionuclides for therapy of cancer is of growing interest as the evidence for clinical success of targeted alpha therapy is increasing. The development of methods for the reliable production of alpha emitters in clinically relevant amounts is an important pre-requisite for further development and widespread application of alpha therapy. This session provides the opportunity to present and discuss novel methods for the production of alpha emitters, advances in radiolabelling and radiochemistry with alpha emitters, preclinical models in vitro and in vivo and dosimetry with alpha emitters. Particular focus will also be given to clinical experiences with targeted alpha therapy.

INVITED PAPERS

213Bi-DOTATOC receptor targeted alpha-radionuclide therapy induces remission in neuroendocrine tumors refractory to beta-radiation - a first in human study
Frederick Giesel, Radiologische Klinik und Poliklinik, Universitäts-Klinikum Heidelberg, Germany

Investigation of astatine chemistry in solution
Gilles Montavon, Laboratoire Subatech, France

Radioactive nanoparticles
Aleksander Bilewicz, Institute of Nuclear Chemistry and Technology, Poland

Targeted Liposomes Loaded with Actinium-225 for Antivascular Alpha-Particle Therapy
Stavroula Sofou, Biomedical Engineering, Rutgers University, United States

Large-scale production of Actinium-225
Jonathan Engle, Los Alamos National Laboratory, United States